|
1
|
Sun D, Cao M, Li H, He S and Chen W:
Cancer burden and trends in China: A review and comparison with
Japan and South Korea. Chin J Cancer Res. 32:129–139. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smyth EC, Verheij M, Allum W, Cunningham
D, Cervantes A and Arnold D; ESMO Guidelines Committee, : Gastric
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 27 (Suppl 5):v38–v49. 2016. View Article : Google Scholar
|
|
3
|
Muro K, Van Cutsem E, Narita Y,
Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh
KH, et al: Pan-Asian adapted ESMO Clinical Practice Guidelines for
the management of patients with metastatic gastric cancer: A
JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann
Oncol. 30:19–33. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Japanese Gastric Cancer Association, .
Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric
Cancer. 20:1–19. 2017. View Article : Google Scholar
|
|
5
|
Songun I, Putter H, Kranenbarg EM, Sasako
M and van de Velde CJ: Surgical treatment of gastric cancer:
15-year follow-up results of the randomised nationwide Dutch D1D2
trial. Lancet Oncol. 11:439–449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Degiuli M, Sasako M, Ponti A, Vendrame A,
Tomatis M, Mazza C, Borasi A, Capussotti L, Fronda G, Morino M, et
al Italian Gastric Cancer Study Group, : Randomized clinical trial
comparing survival after D1 or D2 gastrectomy for gastric cancer.
Br J Surg. 101:23–31. 2014.PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network
(NCCN), . Clinical Practice Guidelines in Oncology. Gastric Cancer.
Version 1. 2020.
|
|
8
|
Liang Y, Cui J, Cai Y, Liu L, Zhou J, Li
Q, Wu J and He D: ‘D2 plus’ lymphadenectomy is associated with
improved survival in distal gastric cancer with clinical serosa
invasion: A propensity score analysis. Sci Rep. 9:191862019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang L, Liang H, Wang X, Li F, Ding X and
Deng J: Risk factors for metastasis to para-aortic lymph nodes in
gastric cancer: A single institution study in China. J Surg Res.
179:54–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang Y, Wu L, Wang X, Ding X, Liu H, Li
B, Wang B, Pan Y, Zhang R, Liu N, et al: Positive impact of adding
no.14v lymph node to D2 dissection on survival for distal gastric
cancer patients after surgery with curative intent. Chin J Cancer
Res. 27:580–587. 2015.PubMed/NCBI
|
|
11
|
Masuda TA, Sakaguchi Y, Toh Y, Aoki Y,
Harimoto N, Taomoto J, Ikeda O, Ohga T, Adachi E and Okamura T:
Clinical characteristics of gastric cancer with metastasis to the
lymph node along the superior mesenteric vein (14v). Dig Surg.
25:351–358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu L, Zhang C, Liang Y, Wang X, Ding X and
Liang H: Risk factors for metastasis to no.14v lymph node and
prognostic value of 14v status for gastric cancer patients after
surgery. Jpn J Clin Oncol. 48:335–342. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sasako M, Sano T, Yamamoto S, Kurokawa Y,
Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai
K, et al Japan Clinical Oncology Group, : D2 lymphadenectomy alone
or with para-aortic nodal dissection for gastric cancer. N Engl J
Med. 359:453–462. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yonemura Y, Wu CC, Fukushima N, Honda I,
Bandou E, Kawamura T, Kamata T, Kim BS, Matsuki N, Sawa T, et al
East Asia Surgical Oncology Group, : Randomized clinical trial of
D2 and extended paraaortic lymphadenectomy in patients with gastric
cancer. Int J Clin Oncol. 13:132–137. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kakeji Y, Korenaga D, Baba H, Watanabe A,
Tsujitani S, Maehara Y and Sugimachi K: Surgical treatment of
patients with gastric carcinoma and duodenal invasion. J Surg
Oncol. 59:215–219. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tokunaga M, Ohyama S, Hiki N, Fukunaga T,
Inoue H, Yamada K, Sano T, Yamaguchi T and Nakajima T: Therapeutic
value of lymph node dissection in advanced gastric cancer with
macroscopic duodenum invasion: Is the posterior pancreatic head
lymph node dissection beneficial? Ann Surg Oncol. 16:1241–1246.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kumagai K, Sano T, Hiki N, Nunobe S,
Tsujiura M, Ida S, Ohashi M and Yamaguchi T: Survival benefit of
‘D2-plus’ gastrectomy in gastric cancer patients with duodenal
invasion. Gastric Cancer. 21:296–302. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Japanese Gastric Cancer Association, .
Japanese Classification of Gastric Carcinoma - 2nd English Edition
-. Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Japanese Gastric Cancer Association, .
Japanese classification of gastric carcinoma: 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
An JY, Pak KH, Inaba K, Cheong JH, Hyung
WJ and Noh SH: Relevance of lymph node metastasis along the
superior mesenteric vein in gastric cancer. Br J Surg. 98:667–672.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Japanese Gastric Cancer Association, .
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric
Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eom BW, Joo J, Kim YW, Reim D, Park JY,
Yoon HM, Ryu KW, Lee JY and Kook MC: Improved survival after adding
dissection of the superior mesenteric vein lymph node (14v) to
standard D2 gastrectomy for advanced distal gastric cancer.
Surgery. 155:408–416. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen QY, Zheng CH, Li P, Xie JW, Wang JB,
Lin JX, Lu J, Cao LL, Lin M, Tu RH, et al: Safety and prognostic
impact of prophylactic laparoscopic superior mesenteric vein (no.
14v) lymph node dissection for lower-third gastric cancer: A
propensity score-matched case-control study. Surg Endosc.
32:1495–1505. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han WH, Joo J, Eom BW, Ryu KW, Kim YW,
Kook MC and Yoon HM: Factors associated with metastasis in superior
mesenteric vein lymph node in subtotal gastrectomy for gastric
cancer: Retrospective case control study. Chin J Cancer Res.
32:43–50. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kong SH, Yoo MW, Kim JW, Lee HJ, Kim WH,
Lee KU and Yang HK: Validation of limited lymphadenectomy for
lower-third gastric cancer based on depth of tumour invasion. Br J
Surg. 98:65–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abe I, Kinoshita T, Kaito A, Sunagawa H,
Watanabe M, Sugita S, Tonouchi A and Sato R: Five-year survival
associated with stage I gastric cancer after resection of early
recurrence at nodal Station no. 14v: A case report. J Gastric
Cancer. 17:186–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen QY, Huang CM, Lin JX, Zheng CH, Li P,
Xie JW, Wang JB, Lu J and Yang XT: Laparoscopic infrapyloric area
lymph node dissection with no. 14v enlargement for advanced lower
gastric cancer in middle colic vein approach. Ann Surg Oncol.
23:9512016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng C, Gao ZM, Sun AQ, Huang HB, Wang
ZN, Li K and Gao S: Prognostic significance of 14v-lymph node
dissection to D2 dissection for lower-third gastric cancer. World J
Clin Cases. 7:2712–2721. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tokunaga M, Ohyama S, Hiki N, Fukunaga T,
Aikou S and Yamaguchi T: Can superextended lymph node dissection be
justified for gastric cancer with pathologically positive
para-aortic lymph nodes? Ann Surg Oncol. 17:2031–2036. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang C, He Y, Schwarz RE, Smith DD, Wang
L, Liu F and Zhan W: Evaluation of para-aortic nodal dissection for
locoregionally advanced gastric cancer with 1–3 involved
para-aortic nodes. Chin Med J (Engl). 127:435–441. 2014.PubMed/NCBI
|
|
31
|
Oyama K, Fushida S, Kinoshita J, Makino I,
Nakamura K, Hayashi H, Nakagawara H, Tajima H, Fujita H, Takamura
H, et al: Efficacy of pre-operative chemotherapy with docetaxel,
cisplatin, and S-1 (DCS therapy) and curative resection for gastric
cancer with pathologically positive para-aortic lymph nodes. J Surg
Oncol. 105:535–541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu JK, Yang K, Zhang B, Chen XZ, Chen ZX
and Chen JP: D2 plus para-aortic lymphadenectomy versus
standardized D2 lymphadenectomy in gastric cancer surgery. Surg
Today. 39:207–213. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang H and Deng J: Evaluation of rational
extent lymphadenectomy for local advanced gastric cancer. Chin J
Cancer Res. 28:397–403. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen XZ, Hu JK, Zhou ZG, Rui YY, Yang K,
Wang L, Zhang B, Chen ZX and Chen JP: Meta-analysis of
effectiveness and safety of D2 plus para-aortic lymphadenectomy for
resectable gastric cancer. J Am Coll Surg. 210:100–105. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nunobe S, Ohyama S, Sonoo H, Hiki N,
Fukunaga T, Seto Y and Yamaguchi T: Benefit of mediastinal and
para-aortic lymph-node dissection for advanced gastric cancer with
esophageal invasion. J Surg Oncol. 97:392–395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Roviello F, Pedrazzani C, Marrelli D, Di
Leo A, Caruso S, Giacopuzzi S, Corso G and de Manzoni G:
Super-extended (D3) lymphadenectomy in advanced gastric cancer. Eur
J Surg Oncol. 36:439–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morita S, Fukagawa T, Fujiwara H and Katai
H: The clinical significance of para-aortic nodal dissection for
advanced gastric cancer. Eur J Surg Oncol. 42:1448–1454. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Marrelli D, Ferrara F, Giacopuzzi S,
Morgagni P, Di Leo A, De Franco L, Pedrazzani C, Saragoni L, De
Manzoni G and Roviello F: Incidence and Prognostic Value of
Metastases to ‘Posterior’ and para-aortic lymph nodes in resectable
gastric cancer. Ann Surg Oncol. 24:2273–2280. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaito A, Kinoshita T, Tokunaga M, Sunagawa
H, Watanabe M, Sugita S, Tonouchi A, Sato R, Abe I and Akimoto T:
Prognostic factors and recurrence pattern of far-advanced gastric
cancer with pathologically-positive para-aortic lymph nodes.
Anticancer Res. 37:3685–3692. 2017.PubMed/NCBI
|
|
40
|
Tsuburaya A, Mizusawa J, Tanaka Y,
Fukushima N, Nashimoto A and Sasako M; Stomach Cancer Study Group
of the Japan Clinical Oncology Group, : Neoadjuvant chemotherapy
with S-1 and cisplatin followed by D2 gastrectomy with para-aortic
lymph node dissection for gastric cancer with extensive lymph node
metastasis. Br J Surg. 101:653–660. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fujiwara Y, Omori T, Demura K, Miyata H,
Sugimura K, Ohue M, Kobayashi S, Takahashi H, Doki Y and Yano M: A
multidisciplinary approach for advanced gastric cancer with
paraaortic lymph node metastasis. Anticancer Res. 35:6739–6745.
2015.PubMed/NCBI
|
|
42
|
He Q, Ma L, Li Y and Li G: A pilot study
of an individualized comprehensive treatment for advanced gastric
cancer with para-aortic lymph node metastasis. BMC Gastroenterol.
16:82016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
de Manzoni G, Di Leo A, Roviello F,
Marrelli D, Giacopuzzi S, Minicozzi AM and Verlato G: Tumor site
and perigastric nodal status are the most important predictors of
para-aortic nodal involvement in advanced gastric cancer. Ann Surg
Oncol. 18:2273–2280. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nomura E, Sasako M, Yamamoto S, Sano T,
Tsujinaka T, Kinoshita T, Furukawa H, Shimizu T, Hiratsuka M,
Kobayashi O, et al Gastric Cancer Surgical Study Group of the Japan
Clinical Oncology Group, : Risk factors for para-aortic lymph node
metastasis of gastric cancer from a randomized controlled trial of
JCOG9501. Jpn J Clin Oncol. 37:429–433. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shinkai M, Imano M, Chiba Y, Iwama M,
Shiraisi O, Yasuda A, Tsubaki M, Nishida S, Kimura Y and Yasuda T:
Phase II trial of neoadjuvant chemotherapy with intraperitoneal
paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage
IIIA or IIIB gastric cancer. J Surg Oncol. 119:56–63. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Reddavid R, Sofia S, Chiaro P, Colli F,
Trapani R, Esposito L, Solej M and Degiuli M: Neoadjuvant
chemotherapy for gastric cancer. Is it a must or a fake? World J
Gastroenterol. 24:274–289. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Endo S, Ikenaga M, Yamada T, Tamura S and
Sasaki YO: Prognostic factors for para-aortic lymph node dissection
after neoadjuvant chemotherapy for gastric cancer. Anticancer Res.
40:2351–2357. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP,
Kim BS, Yoo MW, Yook JH, Kim BS, Kim J, et al: Phase II study of
induction chemotherapy with docetaxel, capecitabine, and cisplatin
plus bevacizumab for initially unresectable gastric cancer with
invasion of adjacent organs or paraaortic lymph node metastasis.
Cancer Res Treat. 50:518–529. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zheng XH, Zhang W, Yang L, Du CX, Li N,
Xing GS, Tian YT and Xie YB: Role of D2 gastrectomy in gastric
cancer with clinical para-aortic lymph node metastasis. World J
Gastroenterol. 25:2338–2353. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shen DF, Chen DW, Quan ZW, Dong P, Wang
XF, Xu HZ, Zhao ML and Chen L: Dissection of no. 13 lymph node in
radical gastrectomy for gastric carcinoma. World J Gastroenterol.
14:936–938. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Eom BW, Joo J, Kim YW, Park B, Park JY,
Yoon HM, Lee JH and Ryu KW: Is there any role of additional
retropancreatic lymph node dissection on D2 gastrectomy for
advanced gastric cancer? Ann Surg Oncol. 20:2669–2675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Saito H, Kono Y, Murakami Y, Shishido Y,
Kuroda H, Matsunaga T, Fukumoto Y, Osaki T, Ashida K and Fujiwara
Y: Therapeutic value of lymph node dissection along the superior
mesenteric vein and the posterior surface of the pancreatic head in
gastric cancer located in the lower third of the stomach. Yonago
Acta Med. 61:175–181. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sasako M, McCulloch P, Kinoshita T and
Maruyama K: New method to evaluate the therapeutic value of lymph
node dissection for gastric cancer. Br J Surg. 82:346–351. 1995.
View Article : Google Scholar : PubMed/NCBI
|
